Clinical Trials Browser

Phase 2 × Osteosarcoma × Ipilimumab × Clear all

NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05302921 2025-01-01

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Phase 2 Completed

5 enrolled

CNSDermatologicGastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Melanoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02982486 2017-11-01

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Phase 2 Unknown

60 enrolled

GastrointestinalSarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor